EyePoint Pharmaceuticals launches Dexycu commercially in the US: 3 key details

EyePoint Pharmaceuticals commercially launched Dexycu, and intraocular steroid for postoperative inflammation following cataract surgery.

The key details to know:

1. Dexycu replaces long-dose steroid eye drops which can require patients to administer them four times a day and titrating down over four weeks, which can lead to low compliance.

2. Dexycu's launch will be phased, with cataract surgery experts included in the initial phase ahead of the release to the wider ophthalmology community.

3. CMS released an updated reimbursement J-code for Dexycu, J1095, through the Healthcare Common Procedure Coding System.

More articles on supply chain:
ASC supply chain tip of the day: Leverage market share & volume
Are you a materials manager or managed by your materials?
Olio raises $2.5M to expand post-acute collaboration platform — 3 insights

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Top 40 Articles from the Past 6 Months